You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for FITM
FITM is a potent and selective negative allosteric modulator of mGlu1 receptors (IC50 = 5.1 nM). Displays >1300-fold selectivity for mGlu1 over other metabotropic glutamate receptors (IC50 values are 7 μM and >10 μM for mGlu5 and mGlu2 or mGlu8, respectively). Antagonizes methamphetamine-induced locomotion in mice.
Compound Libraries for FITM
Technical Data for FITM
|Store at -20°C
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for FITM
|Max Conc. mg/mL
|Max Conc. mM
Preparing Stock Solutions for FITM
The following data is based on the product molecular weight 371.43. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass
References for FITM
References are publications that support the biological activity of the product.
Satoh et al (2009) Discovery and in vitro and in vivo profiles of 4-fluoro-N-[4-[6-(isopropylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-N-methylbenzamide as novel class of an orally active metabotropic glutamate receptor 1 (mGluR1) antagonist. Bioorg.Med.Chem.Lett. 19 5464 PMID: 19674894
Wu et al (2014) Structure of a class C GPCR metabotropic glutamate receptor 1 bound to an allosteric modulator. Science. 344 58 PMID: 24603153
If you know of a relevant reference for FITM, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: FITM, FITM supplier, potent, selective, negative, allosteric, modulator, antagonist, mGlu1, group, I, metabotropic, glutamate, receptor, Glutamate, (Metabotropic), Group, Receptors, 6859, Tocris Bioscience
Citations for FITM
Citations are publications that use Tocris products.
Currently there are no citations for FITM. Do you know of a great paper that uses FITM from Tocris? Please let us know.
Reviews for FITM
There are currently no reviews for this product. Be the first to review FITM and earn rewards!
Have you used FITM?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.